Goldman Sachs Maintains Buy on AbCellera Biologics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has maintained a 'Buy' rating on AbCellera Biologics (NASDAQ:ABCL) but lowered the price target from $27 to $24.
August 04, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on AbCellera Biologics but lowered the price target from $27 to $24.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100